ReviewWorld journal of gastroenterology2016
Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association.
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 62 citations in OpenAlex.
- [Histological and clinical overlap of hidradenitis suppurativa and Crohn disease under IL-17 inhibition].Dermatologie (Heidelberg, Germany) · 2025Article
- Unravelling the Link Between Hidradenitis Suppurativa and Inflammatory Bowel Disease: A Literature Review.Biomedicines · 2025Review
- The Correlation between Hidradenitis Suppurativa and Irritable Bowel Diseases: A Systematic Review.The Journal of clinical and aesthetic dermatology · 2025Review
- Demographics, Comorbidity, Treatment, Healthcare Resource Utilization, and Costs Analysis of Hidradenitis Suppurativa in Dubai.Dermatology (Basel, Switzerland) · 2025Article
- Clinical Epidemiology and Phenotypic Characteristics of Hidradenitis Suppurativa Disease in the Central Region of Saudi Arabia: Findings from a Cross-Sectional.Clinical, cosmetic and investigational dermatology · 2025Article
- Coexisting autoimmune disorders among patients with inflammatory bowel disease at a tertiary center in Saudi Arabia: A cross-sectional study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Comorbidities, Clinical Presentation, Subtypes, and Treatment of HS Patients in Lithuania.Journal of clinical medicine · 2024Article
- Bacterial Metabolites and Inflammatory Skin Diseases.Metabolites · 2023Review
- How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease.Journal of clinical medicine · 2022Review
- Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations.Therapeutic advances in gastroenterology · 2022Review
- Management of Severe Hidradenitis Suppurativa.Cureus · 2021Article
- Tumescent triamcinolone infiltration: A new approach for the management of recalcitrant hidradenitis suppurativa.JAAD case reports · 2020Article
- Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM).Journal of clinical medicine · 2019Article
- Review
- [Prevalence of ten Immune-mediated inflammatory diseases (IMID) in Spain].Revista espanola de salud publica · 2019Article
- Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms.Therapeutic advances in chronic disease · 2019Review
- Acute fatty liver of pregnancy in a woman with ulcerative colitis and familial hidradenitis suppurativa.Obstetric medicine · 2018Article
- Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.Digestive diseases and sciences · 2018Review
- [Cutaneous involvement in chronic inflammatory bowel disease : Crohn's disease and ulcerative colitis].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2016Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) could be associated with several extra-intestinal manifestations (EIMs) involving musculoskeletal, hepatopancreatobiliary, ocular, renal, and pulmonary systems, as well as the skin. In the last years, hidradenitis suppurativa (HS) is acquiring an increasing interest. IBD, especially Crohn's disease (CD), is among the most reported associated diseases in HS patients. The aim of this paper is to give a brief overview of data showing a possible epidemiologic and pathogenetic association between IBD and HS. We performed a pooled-data analysis of four studies and pooled prevalence of HS in IBD patients was 12.8%, with a 95%CI of 11.7%-13.9%. HS was present in 17.3% of subjects with CD (95%CI: 15.5%-19.1%) and in 8.5% of UC patients (95%CI: 7.0%-9.9%). Some items, especially altered immune imbalance, are generally involved in IBD pathogenesis as well as invoked by HS. Smoking is one of the most relevant risk factors for both disorders, representing a predictor of their severity, despite, actually, there being a lack of studies analyzing a possible shared pathway. A role for inheritance in HS and CD pathogenesis has been supposed. Despite a genetic susceptibility having been demonstrated for both diseases, further studies are needed to investigate a genetic mutual route. Although the pathogenesis of IBD and HS is generally linked to alterations of the immune response, recent findings suggest a role for intestinal and skin microbiota, respectively. In detail, the frequent finding of Staphylococcus aureus and coagulase-negative staphylococci on HS cutaneous lesions suggests a bacterial involvement in disease pathogenesis. Moreover, microflora varies in the different cutaneous regions of the body and, consequently, two different profiles of HS patients have been identified on these bases. On the other hand, it is well-known that intestinal microbiota may be considered as "the explosive mixture" at the origin of IBD despite the exact relationship having not been completely clarified yet. A better comprehension of the role that some bacterial species play in the IBD pathogenesis may be essential to develop appropriate management strategies in the near future. A final point is represented by some similarities in the therapeutic management of HS and IBD, since they may be controlled by immunomodulatory drugs. In conclusion, an unregulated inflammation may cause the lesions typical of both HS and IBD, particularly when they coexist. However, this is still a largely unexplored field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.